JP2025506143A5 - - Google Patents

Info

Publication number
JP2025506143A5
JP2025506143A5 JP2024547227A JP2024547227A JP2025506143A5 JP 2025506143 A5 JP2025506143 A5 JP 2025506143A5 JP 2024547227 A JP2024547227 A JP 2024547227A JP 2024547227 A JP2024547227 A JP 2024547227A JP 2025506143 A5 JP2025506143 A5 JP 2025506143A5
Authority
JP
Japan
Application number
JP2024547227A
Other languages
Japanese (ja)
Other versions
JPWO2023154730A5 (https=
JP2025506143A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062185 external-priority patent/WO2023154730A2/en
Publication of JP2025506143A publication Critical patent/JP2025506143A/ja
Publication of JP2025506143A5 publication Critical patent/JP2025506143A5/ja
Publication of JPWO2023154730A5 publication Critical patent/JPWO2023154730A5/ja
Pending legal-status Critical Current

Links

JP2024547227A 2022-02-09 2023-02-08 多重特異性結合性作用剤およびその使用 Pending JP2025506143A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263308485P 2022-02-09 2022-02-09
US63/308,485 2022-02-09
US202263425960P 2022-11-16 2022-11-16
US63/425,960 2022-11-16
PCT/US2023/062185 WO2023154730A2 (en) 2022-02-09 2023-02-08 Multispecific binding agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2025506143A JP2025506143A (ja) 2025-03-07
JP2025506143A5 true JP2025506143A5 (https=) 2026-02-13
JPWO2023154730A5 JPWO2023154730A5 (https=) 2026-02-13

Family

ID=87565080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547227A Pending JP2025506143A (ja) 2022-02-09 2023-02-08 多重特異性結合性作用剤およびその使用

Country Status (6)

Country Link
US (1) US20250197502A1 (https=)
EP (1) EP4475886A4 (https=)
JP (1) JP2025506143A (https=)
AU (1) AU2023219697A1 (https=)
CA (1) CA3243802A1 (https=)
WO (1) WO2023154730A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof
WO2025133389A1 (en) * 2023-12-22 2025-06-26 Numab Therapeutics AG Antibody binding domains having specificity for lilrb2
EP4574844A1 (en) * 2023-12-22 2025-06-25 Numab Therapeutics AG Multispecific antibodies having specificity for cd47 and pdl1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EA039662B1 (ru) * 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
KR20210096612A (ko) * 2018-10-29 2021-08-05 티가티엑스, 인크. IgA 항체 구축물을 포함하는 조성물 및 방법
AU2021205440A1 (en) * 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof

Similar Documents

Publication Publication Date Title
JP2025506143A5 (https=)
BR202022009269U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13174U (https=)
BY13160U (https=)
BY13159U (https=)
BY13158U (https=)
BY13157U (https=)
BY13156U (https=)
CN307049723S (https=)
CN307049691S (https=)
BY13155U (https=)
CN307049067S (https=)
CN307047880S (https=)
CN307047327S (https=)
CN307046855S (https=)
BY13135U (https=)
BY13153U (https=)
CN307046245S (https=)
CN307045197S (https=)
BY13152U (https=)
CN307044755S (https=)
BY13151U (https=)
BY13150U (https=)